American Medical Systems Holdings, Inc. (AMMD) recently won a new contract to supply three of its female stress urinary incontinence (SUI) treatment devices, Monarc Subfascial Hammock, MiniArc Single-Incision Sling, and SPARC Sling System, in the U.K. The contract was awarded by the public healthcare provider of the U.K. , the National Healthcare Services (NHS), as part of its multiple-awardees contract. Financial details of the contract are yet to be disclosed.  The devices will be available to women treated in any NHS hospital in the region and supported by the Normanton centre, U.K. The Monarc device is one of the leading transobturator slings that bring relief to women suffering from SUI. It has been estimated that more than 600,000 women have been implanted with the Monarc, MiniArc and SPARC systems globally.  We think that the new contract is a shot in the arm for American Medical Systems ...

Nephros, Inc.

(OTC: NEPH)

A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with three pending FDA decisions. If you are an avid investor of pre-PDUFA companies, StocksHaven Investments highly suggests you conduct some due diligence on this company, as its potential value greatly outweighs the risks involved. About: Nephros, Inc. (Nephros) is engaged primarily in the development of hemodiafiltration (HDF), products and technologies for treating patients with end stage renal disease (ESRD). The Company has three products in various stages of development in the HDF modality to deliver therapy to ESRD patients: OLpur MDHDF filter series (which it sells in various countries in Europe and consists of its MD190 and MD220 diafilters);

...

The Zacks Rank Buys featured last week were: Buffalo Wild Wings, Inc. (...